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1 Introduction
Rapid advances in medical technology have 
made it possible to save the lives of patients who 
have lost one or more vital organs due to severe 
disease, such as cancer, or from serious traffic 
accidents. Many of these patients can even be 
rehabilitated back into society. Future medical 
technology strives to restore lost tissue to its 
original state. Inspired by the famous experiment 
by Vacanti et al. in the United States, in which 
aur icu lar car t i lage was regenerated using 
cell - incorporated biomaterials[1], the medical 
community is experiencing a worldwide boom in 
“regenerative medicine” research. 
Regenerative medicine is a generic term for 
a variety of therapeutic techniques to restore 
lost or damaged organs and tissues due to 
accidents or diseases to their original state, taking 
advantage of the regenerative capacity inherent in 
biological entities. Biomaterial research has two 
lines of investigation: one is to aim at cell/tissue 
regeneration by means of tissue replenishment, 
such as bone marrow transplant, and the other is 
to regenerate tissues using “tissue engineering” 
techniques. Regenerative medicine is advancing 
internationally along these two lines[2]. In this 
context, tissue engineering refers to techniques 
to restore tissues using cells, scaffolds required 
to settle in the body, and cell growth factors. 
Some tissue engineering products have already 
been brought into practical use in the fields of 
skin, cartilage and bone regeneration, and their 
worldwide market size is estimated to be around 
17.1 billion yen. If we include regeneration and 
transplantation of bone, cardiovascular system, 
teeth and organs, the total worldwide market size 
is estimated to reach 250 billion yen by 2015[3]. In 
a separate approach to treat diseases and physical 
damage with minimal invasion, research on drug 
delivery system (DDS) and minimum invasive 
surgery have also shown remarkable progress. 
These next-generation medical technologies will 
contribute immensely to improve the quality of 
life (QOL) of patients, especially those who are 
elderly. These technologies also contribute to 
reduce medical costs associated with prolonged 
admission and visits to hospitals and welfare costs 
associated with nursing care.
Research in tissue engineering has a worldwide 
demand, as does Japan, which has a rapidly aging 
population. In Japan, deployment of medical and 
welfare measures are highly sought after. Almost 
every country is engaged in fierce competition for 
better regenerative medicine. However, the fruits 
of this research are limited to such areas as skin 
(basically a two-dimensional tissue) and cartilage 
(cells occurring in a hypoxic and low-nutrient 
environment). There still remain many challenges 
to be solved, such as a significant difference in 
three-dimensional structure between regenerated 
and natural tissues/organs. 
This article provides an overview of the current 
status of biomaterial research from the nano 
level and discusses challenges and solutions for 
industrialization of biomaterials in Japan.
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2 What are Biomaterials?
Biomaterial is a generic term for a variety of 
materials used for manufacturing artificial organs 
that have direct contact with cells and tissues for 
a relatively long period of time, or those used in 
regenerative medical techniques, which will be 
discussed in later sections of this paper. These 
materials include those applying surfaces of the 
body or connecting the body via tubes, such as 
contact lenses and artificial dialysis membranes, 
as well as implantable devices, such as artificial 
hearts and artificial joints. Figure 1 shows the 
types of artificial tissues and organs currently 
used in the clinical setting[4].
An essential requirement for materials that 
remain in contact with living tissues for a medium 
to long period of time is that they are not harmful 
to tissues and biological activities, which is a 
challenging objective. The toxicity of substances 
implanted in the body must be considered 
differently from those taken orally. For example, 
cooked r ice taken by mouth wi l l  become 
nutrients for the human body, but implanting the 
same cooked rice inside the body (for example, 
under the skin) will give rise to inflammation. 
Thus bioaff inity, or biocompatibil ity of the 
mater ia l ,  i s  the essent ia l  element for the 
development of biomaterials.
It is thus par ticularly important to “use 
materials with molecular structures that are 
similar to those found in the body”. However, 
making a clear demarcation is difficult regarding 
to what extent the pursuit of simi lar ity is 
effective and beyond which it is dangerous. In 
organic chemistry, clever combination of partial 
spatial configuration and functional groups 
can induce reaction with biomolecules, having 
inspired a variety of efforts to develop new drugs 
for alleviating disease symptoms. These drugs, 
however, may have serious side effects.
Cons ider able  e f for t  ha s  been made to  
compensate or regenerate lost functionality 
of living tissues by producing materials and 
developing novel devices thereof using a selected 
range of inorganic, organic, and metal materials, 
giving rise typically in the 1990s to the evolution 
of the concept of regeneration medicine and 
tissue engineering. More recently, there is also 
an effort afoot to produce artificial extracellular 
substrate that is actually required by cells and 
Figure 1 : Prosthetic devices
Quoted from Reference[4], p.15
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tissues utilizing nanoscale control in response 
to needs in the clinical setting. Along this trend, 
“soft nanotechnology” that does not require 
extreme conditions (high temperature/pressure, 
vacuum, etc.) has come into practical use in 
such areas as artificial bones[5] and drug delivery 
systems[6]. Application of biodegradable metal 
materials has also entered into consideration in 
these areas.
3 Current status of regenerative
 medicine of body part/organ
 and biomaterial research
Table 1 summarizes, from the perspective 
of relatively advanced regenerative medicine 
research, the challenge level of regeneration and 
biomaterials used for body parts and organs.
A l mo s t  a l l  l i v i ng  t i s sue s  a r e  m ade  o f  
organic mater ia ls such as proteins, l ipids 
and polysaccharides. Because the method of 
chemically modifying organic polymers (for 
example, by introducing functional groups) 
has been established in many cases, molecular 
structure design of organic materials is more 
feasible for organic biomaterials than for other 
materials, generating a proliferation of organic 
material research. In the area of inorganic 
biomaterials, Japan has attained one of the most 
advanced levels of research in the world. For 
example, artificial bone using hydroxy apatites*1 
was developed in Japan, and artif icial body 
fluids*2 was also first postulated in Japan. In the 
development of organic- inorganic compound 
Table 1 : Challenge level of regeneration of and biomaterials used for tissues/organs
Tissue / 
Organ
Challenge level of regeneration Organic material Inorganic material
Organic-inorganic 
polymer
Skin
Basically two-dimensional tissue. Culture 
is relatively straightforward.
Collagen, synthetic 
biodegradable polymers 
(polylactic acid, etc.)
— —
Cartilage
Extracellular matrices have 
3-dimensional structures, but there 
are no blood vessels in cartilage 
tissues. Cartilage cells are tolerant to 
low-oxygen, low-nutrient environment, 
making it relatively easy to perform 
3-dementional culture.
Polysaccharides (collagen, 
chondroitin sulfate), synthetic 
biodegradable polymers 
(polylactic acid, etc.)
—
Collagen / 
polysaccharide, 
collagen / 
polysaccharide / 
hydroxyl apatite
Bone
Extracellular matrices have 
3-dimensional structures containing 
blood vessels. Difficulty in sustaining 
cellular activity and function in the 
central porous core.
Collagen, synthetic 
biodegradable polymers 
(polylactic acid, etc.)
Calcium phosphate 
(hydroxyl apatite, 
β-tricalcium phosphate,
α-tricalcium phosphate)
Biodegradable 
polymers/calcium 
phosphate, 
collagen/calcium 
phosphate
Pancreas
Almost no extracellular matrices exist. 
The organ has two parts: the exocrine 
system secreting proteases for digestion 
and the endocrine system (pancreatic 
islets) secreting insulin and other 
hormones. Current research focuses 
on regeneration of pancreatic islets 
that produce insulin used for diabetic 
treatment.
Hydrophilic polymers 
(polyethylene glycol, etc.) 
and hydrophobic polymers 
(coating) for culture plates. 
Agarose as immunoisolation 
membrane.
Silica gel hollow 
beads used as 
immunoisolation 
membrane
Agarose / 
polystylene 
sulfonate as 
immunoisolation 
membrane
Liver
Almost no extracellular matrices exist. 
Regeneration is difficult because of the 
extensive vascular networks and large 
blood flow..
Hydrophilic polymer 
(polyethylene glycol, etc.) 
and hydrophobic polymers 
(coating) for culture plates. 
Temperature-responsive 
culture plate for regeneration 
of 2-dimensional liver cell 
sheet.
Apatite porous media 
used for liver cell 
culture
—
Capillary 
blood 
vessel
Regeneration of capillaries is difficult 
to regenerate because of the small 
tubular structure consisting of 3 different 
layers, but capillaries are necessary for 
survival of regenerated organs. Vascular 
endothelial cells are the most common 
target of tissue engineering.
Patterned culture plates 
capable of regulating cell 
adhesion. Hydrogel-cell 
compositions. Synthetic 
biodegradable polymer 
nanofibers used as scaffolds 
for cell culture.
— —
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materials, Japan also occupies a top level in the 
world.
The following summarizes the current status of 
research and challenges in roughly the order of 
attainability.
3-1 Skin
T he  sk i n  s y s tem i s  compr i s ed  o f  t wo  
components: epidermis and dermis, as shown 
in the accompanying Figure 2[7]. Epidermis, or 
scarfskin, has a thickness of 0.1-0.2 mm (palms 
and soles have thicker scarfskin, from 0.8 to 1.5 
mm), in which cells originated by cell division 
in the innermost part move toward the surface, 
gradually cornifying, and finally fall off from the 
skin surface. Dermis or inner skin, in contrast, 
consists of meticulously woven collagen fibers 
and elastic fibers protecting blood and lymph 
vessels as well as providing a tough and elastic 
texture.
Skin can lose its elements due to burn injury 
and decubitus (bedsores). Skin loss is classified 
into epidermis loss and full-thickness skin loss, 
depending on the depth of the layers lost. The 
former can be effectively cured by grafting 
cultured skin containing only epidermis cells. 
Skin general ly has the resi l ient capacity of 
regeneration and, because of the thin tissue layer, 
skin rarely has difficulties in culturing such as 
necrosis of the core due to insufficient exchange 
of nutrients and gases. Cultured skin has practical 
worldwide applications, including in Japan. 
Although artificial skin has not been approved in 
Japan, we have many cases where patients’ own 
skin is cultured and grafted onto themselves. 
In emergency cases such as extensive burn, a 
common practice is to temporarily graft cultured 
skin from another person and later replace it with 
the patient’s own cultured skin tissues.
For decubitus treatment, a porus collagen 
sponge layer coated with polymers such as silicon 
on one side to reinforce the membrane is used to 
regenerate an artificial epidermis, in which cells 
and tissues attach on the surface and migrate into 
internal pores of the collagen sponge layer to 
produce an epidermis-like layer. For enhancing 
the efficacy of this treatment, some specialists 
immerse the collagen layer in bone marrow fluid 
taken from the patient to induce active tissue 
regeneration. These methods using collagen 
sponges can be useful in emergency cases, but 
subsequent partial skin grafting from other parts 
of the body or cultured skin grafting is required 
after the arti f icial dermis layer has grown. 
Figure 2 : Cross-sectional view of human skin
Quoted from Reference[7], p.254
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Although skin treatment is a relatively advanced 
area among regenerative medical techniques, it 
still has many challenges, such as a prolonged 
treatment period required due to repeated 
operations.
To shorten the period required for a complete 
cure, new types of cultured dermis and cultured 
skin consisting of dermis and epidermis have 
been developed using collagen as a scaffold 
mater ial*3. These cultured skin substitutes 
have shown good results experimentally, and 
considerable effort is being invested towards 
commercia l ization. In Japan, Japan Tissue 
Engineering Co., Ltd. ( J-TEC) and BCS, Inc. are 
aiming at bringing the technique into clinical 
application, and the regenerated skin from J-TEC 
is expected to obtain official approval by the 
end of 2007. Skin regeneration is in a relatively 
advanced stage both in technique and materials, 
but currently available artificial skins does not 
include skin appendages, such as sweat glands, 
sebaceous glands and hair follicles. Research and 
development for regenerating skin containing 
these appendages and developing suitable 
scaffold materials is needed. The aesthetic aspect 
should also be an important consideration for 
new generation regenerative skins.
The number of  pat ients  requ i r ing sk in 
transplantation because of scars or ulcerations 
in Japan is estimated to be around 35,000, and 
the forecast is that the number will remain at the 
same level until 2020. Another forecast indicates 
that about 30% of these patients will use cultured 
skin in 2020, and the market size of cases is 
expected to grow to the level of 5.4 billion yen. 
Extending cultured skin applications to patients 
with burn and traumatic skin damage will result 
in a market size several times larger than this, and 
further extending applications to severe burns 
cases will create an estimated 28.5 billion yen 
market in 2020[8].
3-2 Cartilage
Cartilage consists of cells and substrate, with 
the cells distributed among the substrate without 
touching other cells (Figure 3). The cartilage of 
human adults contains 80% of water and does not 
have vascular tissues. The cells take in nutrients 
and oxygen from synovial f luid through the 
perichondrium, and dispose of wastes and carbon 
dioxide in reverse direction. Because the amount 
of nutrients transported using this pathway 
is much smaller than through blood vessels, 
chondrocytes generally have greater tolerance 
against nutrient/oxygen-depleted environment. 
Organization of cartilage is different for each part 
of the body: hyaline cartilage (Figure 3-a) is found 
in joints, fiber-rich elastic cartilage (Figure 3-b) 
is found in the earlobe, and fibrocartilage (Figure 
3-c), which contains type-I collagen and shows 
strong tolerance against pressure, is found in 
tendons in meniscuses and interspinal disks and 
ligament tissues.
Hyal ine car t i lage t issues main ly consist 
of polysaccharides such as hyaluronic acid, 
chondroitin sulfate and keratan sulfate, and 
collagen. Polysaccharides account for 10% of total 
dry weight, and collagen 60%. Collagen that holds 
the shape of hyaline cartilage is type-II, whose 
ability to form fibers is lower than type-I found in 
Figure 3 : Schematic view of cartilage tissue
a: hyaline cartilage  b: elastic cartilage  c: fibrocartilage
Quoted from Reference[7], p.20
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skin, bone, and fibrocartilage.
Fibrocartilage, if damaged, can be gradually 
restored, except for the f ibrocar t i lage in 
blood - depleted area such as meniscuses and 
interspinal disks. Other cartilages do not have 
the capacity of spontaneous recovery; surgical 
procedures must be taken to restore this tissue. 
Damaged joint car t i lages especia l ly need 
early restoration procedures because they are 
necessary to absorb shocks and allow the smooth 
movement of joints, which directly affect the 
daily activities of the patient*4.
One of the traditional methods for restoration 
is to drill a hole through the subchondral bone 
underlying the damaged joint cartilage into the 
bone marrow, and introduce precursor cells, 
nutr ients and growth factors to regenerate 
fibrocartilage. Although this method can restore 
only the fibrocartilage, it has been widely used 
because it can provide short - term recovery. 
However, since the long- term prevalence of 
arthrosis deformans is high in patients receiving 
such treatment. the mainstream has shifted 
to mosaicplasty, a technique of creating an 
osteochondral autograft by harvesting small 
cylindrical osteochondral plugs from areas of 
normal cartilage on less weight-bearing surfaces 
and inserting them into the defective section 
of cartilage. This method has the advantage of 
enabling restoration of hyaline cartilage, but the 
portion of cartilage from which the autografts are 
obtained will not restore its original shape and 
the amount of grafts available is limited.
In order to overcome these problems, a method 
to restore cartilage using cultured cells, has 
been commercialized for the first time in the 
field of orthopedics. A small amount of tissue 
is obtained from the patient’s cartilage in a less 
weight-bearing region, and the chondrocytes 
isolated from the tissue are cultured to increase 
cell numbers, and the suspended chondrocytes 
are injected into the cartilage defects covered 
by the patient’s own periostea. Remaining 
problems with this method can be the lowering 
of activity in cultured cells as chondrocytes 
and the fact that this method also produces, 
although small, a defect in the patient’s cartilage. 
One method that has the potential for resolving 
these problems is to use the patient’s own bone 
marrow mesenchymal cel ls and make them 
differentiate to chondrocytes after obtaining a 
sufficient number of mesenchymal cells through 
cultivation.
Chondrocytes, being by their nature tolerant 
to oxygen-, nutrient-deficient environment, are 
capable of growing well in three -dimensional 
scaffold materials and producing extracellular 
subst rates.  Di f f icu lt ies  in joint  car t i l age 
regeneration are focused on the adhesion of 
carti lage tissues to subchondral bones, and 
do not include such problems as blood vessel 
introduction and generation of co - operative 
environment for different types of cell species 
(mutual interaction and spatial configuration) as 
in visceral organs. This makes in vitro cartilage 
tissue regeneration relatively easy. This is well 
evidenced in that the experiment by Vacanti et al. 
that produced a “mouse with a human earlobe on 
its back” was a straightforward success. Selection 
of cartilage for the tissue regeneration target was 
the key to the success of this experiment, and this 
success opened the door to development of tissue 
engineering.
In cartilage tissue engineering, chondrocytes or 
bone marrow mesenchymal cells are multiplied 
in the scaffold materials suited for this purpose 
to regenerate, by adding growth factors and 
mechanical stimuli, cartilage tissue containing 
appropriate cartilage substrate. Joint cartilage is a 
supporting organ that always receives mechanical 
stimuli to support the body. Attempts are also 
being made to regenerate bone tissue beneath the 
cartilage tissue to ensure tight adhesion to the 
subchondral bone.
In most cases,  synthet ic biodegradable 
p o l y m e r s  ( e . g . ,  p o l y l a c t i c  a c i d  a n d  
polylactic-glycolic acid copolymer) and collagen 
sponges have been utilized for scaffold materials; 
more contributions from biomaterials to cartilage 
tissue engineering are desired. Gels with similar 
chemical composition to cartilage substrate 
(for example, mixtures of type II collagen and 
hyaluronic acid)[9] have been developed for use 
as scaffolds for cartilage tissue engineering. 
However, to cope with a wider range of cartilage 
defects, the mechanical environment similar 
to actual cartilage is also important as well as 
the chemical environment. Composition and 
56
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
57
Q U A R T E R L Y  R E V I E W  N o . 2 4  /  J u l y  2 0 0 7
structural characteristics of the scaffold material 
affects the responses of scaffold and artificial 
extracellular substrates against mechanical stress, 
and may result in transmission of inappropriate 
mechanical stimuli to the cells. Further study of 
appropriate scaffold materials is needed.
Regeneration of elastic carti lage, such as 
earlobes, garners attention from its aesthetic 
aspects, but we have had no elastic cartilage 
substitutes to date. The most difficult challenge 
in development of cartilage substitutes could 
be interspina l  d i sk regenerat ion.  A mong 
cartilage tissues, the interspinal disk has the 
most complex structure consisting of a central 
pulpy nucleus and surrounding rings of fibrous 
cartilage (fibrous rings), with a set of hyaline 
cartilages sandwiching them from above and 
below prov id ing connect ion with bones.  
Achieving regeneration and functioning of such 
a complex structure in a relatively short period 
of time will require the development of suitable 
scaffold materials and tissues that have been 
sufficiently matured in an in vitro environment. 
Joint cartilage has a four- layer structure with 
each layer having a different cell distribution 
and microstructure: surface layer, intermediate 
layer, deep layer (zona radiata), and calcified 
layer (a layer connecting the cartilage and the 
underlying subchondral bone). Observation at 
the nanoscale level shows that the layers have a 
network of type-II collagen for maintaining its 
structural integrity and nanoscopic structure for 
incorporating polysaccharides that help retain 
water. Development of materials with structural 
characteristics similar to natural joint cartilages 
will be required to ensure the development 
of cartilage function immediately after graft 
implantation as well as the maintenance of 
functions of cultured chondrocytes. 
We have 500 to 600 thousand patients with 
degenerative arthritis in Japan and approximately 
10 % of them are considered t reatable by 
implanting relatively small regenerated cartilage 
grafts that current technology can provide. This 
market size is estimated to be approximately 60 
billion yen. There is room for extending patient 
coverage by improving current technology, but 
the room for the increase of curable patients 
is estimated to be 20% at most (approximately 
100 billion yen market)[8]. If bone regeneration 
technology is developed for practical use, 
combination of bone and carti lage therapy 
embraces nearly all patients, including those who 
suffer from rheumatoid arthritis (approximately 
280 thousand patients), and the market size is 
likely to reach 1,000 billion yen.
3-3 Bone
Bones carry important mechanical functions 
of supporting the body and protecting vital 
organs, such as the brain, heart, lungs and 
central nervous system. Another important 
function is to provide storage of calcium and 
phosphorus. Homeostasis of calcium depends 
heavi ly on the bones. Extracel lular matr ix 
of the bone consists main ly on inorganic 
non - stoich iometr ic carbonate - conta in ing 
hydroxyapatites and type-I collagen. As shown 
in Figure 4, the nano-structure of bone consists 
of apatite nano -crystals arranged on collagen 
fiber in roughly the same orientation. These 
nano -scale composite fibers are arranged in a 
random fashion in spongy bones. In cortical 
bones, they are bundled together in the shape 
of a sheet with all the fibers aligned in the same 
direction, and the sheets are stacked in mutually 
different orientations to form a cylinder- like 
structure of several centimeters in length. Blood 
vessels run in the center of the cylinder, and 
spaces between the fiber sheets are filled with 
osteoclasts. This unit is called an osteon. Osteons 
are renewed continuously; this process is called 
bone remodel ing. Bone remodel ing begins 
with dissolution of apatite crystals in an old or 
a broken bone by osteoclasts and subsequent 
decomposition and absorption of collagen fibers. 
Then, osteoblasts form new bone and fill the 
eroded cavities, and as the new bone ripens and 
osteoblastic cell changes to bone cell with time, 
the cylinder-like layer structure develops finally 
forming a new osteon. Bone remodeling also 
takes place in spongy bones, although osteons are 
not formed in this location.
Guided bone regenerat ion (GBR) is one 
of the preferred methods in dental and oral 
surgery, and good experimental results have 
been reported using polymers, metals, and 
their composite materials. However, owing to 
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the fact that non -biodegradable materials in 
many cases remain in the regenerated tissue, 
this method poses long - term uncertainties. 
Biodegradable materials are much more eligible 
for this purpose. The method that has stood in 
the spotlight in the last decade is composition of 
calcium phosphate that shows good affinity to 
biotissues with synthetic biodegradable polymers. 
The use of these composite materials in GBR 
was proposed around the same time in Italy, 
Germany, and Japan. This method has already 
been clinically applied in Italy, where doctors are 
allowed to exercise a high degree of discretion. 
In Japan, th is is st i l l  in a research phase. 
Membrane materials used for GBR still have much 
room for improvement. Further upgrades are 
desired by, for example, adding growth factors 
and cel l - stimulating factors and improving 
osteoconductive properties.
In a separate development, the tissue engineering 
method for strengthening the connection 
between an artif icial joint and the adjacent 
bone has already been put to practical use in 
Japan. This method harvests stem cells from 
the patient’s bone marrow mesenchymal cells 
that have the potential of differentiating into 
osteoblast cells. After separation and multiplying 
processes, the cultured cells are differentiated by 
adding cell stimulating factors and subsequently 
seeded onto the interface of the artificial joint 
(made of materials, such as alumina, that do not 
directly integrate with the bone) and the bone 
for better connection[10]. Regeneration of a finger 
bone using tissue engineering technique has 
also been reported. However none of these has 
succeeded in regenerating blood vessels in bone 
using tissue engineering methods. In the case of 
the regeneration of a finger bone, the regenerated 
bone does not function as an actual bone. Tissue 
engineering methods capable of restoring major 
bone defects are still in the research phase. 
To some extent for bone defects, a good cure 
can be obtained by autogenous bone graft, or 
grafting the patient’s bones mixed with filling 
materials. Tissue engineering of the bone has two 
main objectives: one is to restore bone defects 
(complete bone defects up to the size of 3-5cm) 
in a relatively short period of time irrespective 
of patient age; the other is in vitro regeneration 
of the whole bone system including cartilage 
Figure 4 : Schematic view of bone structure hierarchy
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and blood vessels. The former objective has an 
aspect of time-game with the development of 
better filling materials. For example, a bone-like 
hydroxyapatite/collagen nanocomposite, with 
nano - structure and chemical composit ion 
similar to the bone and with a self-organization 
mechanism, has an experimental achievement 
of near-perfect restoration of a 2 cm tibial bone 
defect created in a Beagle dog in three months[11]. 
However, unless the cell seeding technique can 
clearly show the promise of more than halving 
restoration period, bone filler technique will be 
used at least for younger generations*5.
In order to make the treatment period shorter 
than that of f i l ler method, development of 
better scaffold materials is essential. These 
scaffolds should also be such materials that can 
be transformed to bone through the function 
of cells in the adjacent bone, because bone is 
rich in extracellular matrix and has to respond 
to mechanical stimuli just as in cartilage, and 
has a high turnover rate,. Organization of bone 
tissue starts with the primary structure at a 
level of nanometer and sequentially develops 
into higher-order structures that can reach the 
size of centimeters. In fact, a complex fiber 
structure of the size up to 75 mm has been 
successfully produced using soft-nanotechnology 
s t a r t i ng f rom a  hydrox yapat i te /col l agen 
nanocomposite[12]. However, bone substitutes 
that mimic bones from micro - to macro -scale 
that contain oriented sheets of fibers and the 
mechanical properties of natural bones have 
not yet been produced. There is a hypothesis 
that substances such as cell stimulation factors 
incorporated in extracellular matrix of bone 
may enhance the function of osteoblasts during 
bone remodeling. At present, such biochemical 
function can be realized only by immobilizing 
molecules on the surface of bulk material. 
More sophisticated function will be needed 
in the future for delivery of an appropriate 
amount of biochemical factors at the correct 
timing. Regeneration of large bone tissues will 
require techniques to regenerate complete 
bone tissues including blood vessels. To solve 
this challenge, development of techniques to 
construct higher-order structure in step -wise 
fashion from nano to macro levels, as well as the 
nano structure construction method that mimics 
biological processes (soft nanotechnology). 
Tech n iques  developed for  solv i ng  these  
challenges are likely to have applications in the 
regeneration of other organs that have scarcely 
any extracellular matrix.
Artificial bone grafts are used in only about 
20% of cases that require bone transplantation. 
The current market size is approximately 7 billion 
yen, and is forecasted to saturate roughly at the 
level of 10 billion yen. However, when the next 
generation artificial bones and tissue engineering 
come of age for practical applications, the 
expectation is that autogenous bone grafting that 
is highly invasive will go out of use, in which 
case the market size (domestic market only) will 
grow to the level of 50 billion yen or more. In the 
United States, the artificial bone market has been 
relatively small because the use of autogenous 
and heterogenous (cadaver) bone transplantation 
has been the dominant method (even heat-treated 
bovine bones are used in some cases). However, 
due to concerns about infectious diseases, the 
demand for artificial ceramic bones has increased 
in the last decade. All these aspects inclusive, the 
size of bone related tissue engineering market 
is likely to reach 300 billion yen. Furthermore, 
regenerated bones using tissue engineering are, 
unlike conventional artificial bones, considered 
applicable for a wider range of patients including 
infants, elderly people and even people with bone 
metabolism disorder, making it possible to boost 
the market size to the level of 600 billion yen.
3-4 Pancreas and Liver
Cells in visceral organs such as the pancreas 
and liver, have very little extracellular matrix: 
interaction between the cel ls plays a more 
important role in expressing the function of cells 
as a component of an organ than in skin, cartilage 
and bones, thus making regeneration through 
tissue engineering techniques more difficult. As 
shown in Figure 5 above, the pancreas is located 
beside the duodenum and its function has two 
aspects: as a part of the digestive system secreting 
pancreatic juice that contains digestive enzymes, 
and as a part of the endocrine system secreting 
insulin and other hormones. The endocrine 
function resides in the pancreatic islets, which 
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are located in the pancreas and consist of one to 
two million cells (See Figure 5 below). 
The liver, shown in Figure 6 above, is involved 
in energy metabolism and detoxication and 
other functions that are essential to life. These 
functions are implemented by the cells and 
vascular system depicted in Figure 6 below[7].
Because regeneration of the liver and pancreas as 
a whole using the currently available technologies 
is next to impossible, the mainstream view to 
solve this problem is to regenerate selected 
minimal functional units and implant them en 
masse to effectively substitute the organ. For 
the pancreas, transplantation of the pancreatic 
islets has a l ready begun for patients with 
insulin-dependent diabetes mellitus or patients 
who cannot produce insulin due to removal of 
pancreas because of cancer or other reasons. 
Among the many attempts to regenerate 
functional units of these v iscera l organs, 
formation of spheroids is attracting attention 
and most  act ively  under development.  A 
spheroid is a mass of cells that are produced 
using non - adherent round - bottom culture 
plates. A variety of techniques is currently 
under consideration to produce high -density 
spheroids with control led cel l behavior. In 
terms of cell culture using nonadhesive plates, 
use of rotating wall vessel and clinostats*6 are 
considered promising, and many attempts are 
being made to produce various types of spheroids 
while controlling their sizes and maintaining 
cell functions. One notable experiment using a 
rotating wall vessel is reported to have succeeded 
in producing hepatocyte spheroids that contain 
blood vessels and biliary tracts starting from 
hepatocytes harvested from a mouse fetus[13]. 
Further development of this experiment is 
being watched closely with expectations. Many 
attempts have been made to produce a large 
amount of spheroids in non-adherent culture 
plates by controlling cell’s adhesive properties[14]. 
This approach is attracting attention because it 
does not require special culture techniques or 
devices.
In parallel to production techniques, the source 
Figure 5 : Pancreas and surrounding organs
Above: Overview     Below: Schematic view of pancreatic islet for insulin production
Quoted from Reference[7], p.155 (above), p.114 (below)
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of cells is also an important matter to consider. In 
many cases, organs become necessary after the 
patient’s own organs fail, making it necessary to 
either differentiate cells from the patient’s own 
stem cells, or to culture another person’s cells. 
In the latter case, the cells and secretion from 
the cells can cause immunological reactions, 
entailing the development of the immunoisolation 
method. These isolation materials have to allow 
necessary components to pass through while 
blocking immune reaction causing substances, 
which is quite a difficult task. For example, 
immunoisolation materials used for the pancreas 
must permeate insulin, nutrient components, and 
waste.
Naturally, regeneration of organs with all the 
original functions and adequate size is the final 
target. For this purpose, the highly desirable aim 
is the development of an auxiliary biomaterials 
that provide a 3-dimensional framework for initial 
organ development and maintains its structural 
integrity until the organ can hold its own shape 
using only the cells and extracellular substrates 
secreted from them.
Figure 6 : Liver organization
Above : Whole image (a: front view, b: bottom view)
Below : Liver lobule (a: vertical section, b: horizontal section)
Quoted from Reference[7], p.156 (above), p.157 (below)
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Let us estimate the size of the pancreas related 
regenerative medicine market from the number 
of diabetic patients. Currently, the estimated 
number of patients is 2.469 million in Japan, 
and 0.246 billion worldwide, and will reach 
0.38 billion in 20 years[15]. Assuming that 10% 
of patients are indicated for artificial pancreas, 
and the cost per patient is around 3 million yen, 
market size would be 84.5 billion yen in Japan[8] 
and 850 billion yen worldwide.
Commercialization of artificial hybrid liver 
(combination of liver cells and biomaterials) is 
underway with a unit price of around 5 million 
yen. These units are estimated to create a 48.8 
billion yen market by 2020[8]. Regenerated liver 
will not only supplant these artificial units, but 
will also increase the percentage of patients 
viable to liver transplantation (including the 
use of regenerated liver) up to 20%. There are 
some 40 thousand patients who need l iver 
transplantation in Japan; thus the market size is 
expected to grow up to around 40 billion yen.
3-5 Challenges of tissue engineering
As described above, culture and multiplication 
of cells as two-dimensional structures is relatively 
stra ightforward, but to develop t issues in 
three-dimensional shapes retaining cell functions 
is extremely difficult. Okano et al. of Tokyo 
Women’s Medical University, who are advocating 
cell sheet engineering, are conducting studies 
on the clinical application of corneal epithelial 
cells that can be brought into practical use with 
two dimensional culture[16]. However, in other 
applications, for example myocardial sheets, 
three-dimensional grafts are quite difficult unless 
lamination process is carried out by repeated 
surgeries. Cells need provision of oxygen and 
nutrient, and they have to dispose of waste 
matter. In the environment without vascular 
system, provision and disposal must depend on 
liquid phase dispersion, causing cell necrosis 
in the core of thick cell mass. Similar problem 
can occur in preparation of large spheroids 
and culture of osteoblasts in three-dimensional 
porous media. Regeneration of clean organs 
requires scaffolds where cells can multiply, 
culture media can be easily exchanged even in 
the core of tissue, and the vascular system can 
develop inside (cartilage excluded). Hitherto, 
efforts have been made, and to some success, to 
provide surface preparation on mono-functional 
scaffold materials for better adhesion properties, 
or simply adding cell stimulus factors to provide 
above-mentioned functionality to the scaffold. To 
date, no attempt to reproduce an organ fragment 
even of the size of 1cm has succeeded. 
Tak ing the above into considerat ion, to 
overcome this one-centimeter barrier, it could be 
useful to produce tissues that perform multiple 
functions containing different types of cells as 
found in the living bodies to provide appropriate 
cell environment over time just as in the natural 
developmental process. Thus, an important 
agenda for material development is to produce 
scaffolds that allow four-dimensional control, 
i.e, three-dimensional control over time. Such 
scaffolds should provide a cell environment 
that can change its state synchronized to, or in 
advance to, the development, differentiation, and 
induction processes of the cells, similar to that of 
actual biological body.
Biodegradable metallic implant materials using 
magnesium alloy are regaining attention. Many 
attempts were made in the 1930s and 1940s 
to apply these alloys to orthopedic materials 
because they have similar Young’s modulus 
as bones. However, these attempts subsided 
gradually for two main reasons: magnesium alloys 
can produce hydrogen that forms air bubbles 
around the implant and the use of stainless steel 
with superior mechanical properties became 
common in starting in the 1940s. In regenerative 
medicine where biodegradability is an important 
factor, magnesium alloys with good mechanical 
strength are an attractive option. In contrast, 
ceramics are also promising in terms of biological 
affinity. The expectation is that combinations 
of ceramics, organic polymers and magnesium 
alloys will help the development of better scaffold 
materials. 
62
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
63
Q U A R T E R L Y  R E V I E W  N o . 2 4  /  J u l y  2 0 0 7
4 Points for improvement of
 biomaterial research and
 practical application
4-1 Official licensing procedures
There is fierce R&D competition taking place 
among nations in the field of biomaterial and 
tissue engineering. Developed nations are aiming 
at rapid introduction of these results to the 
medical and welfare market to cope with their 
aging populations. Regenerative products consist 
of a wide variety of valuable products in small 
quantities.
Our f i rst requirement towards practica l 
appl icat ion of th is research is to develop 
an ef f ic ient and speedy l icensing system 
for biomaterials or medical devices, and to 
participate in efforts to establish international 
standards control l ing the biomater ials and 
medical devices.
A long process is required before biomaterials 
and t issue engineer ing techniques can be 
used cl in ica l ly: A f ter conf i rmation of the 
sa fety and ef f icacy of the invest igat iona l 
material/technique in cell culture assays and 
animal studies, an appl ication for cl in ical 
studies of the material/technique should be 
submitted, and then an application for approval 
of the material/technique containing data in 
human should be approved before marketing 
the material/technique. In Japan, cell -material 
composites for use in regenerative medicine 
are regarded as a “medical device” that contains 
medicinal substances, while materials used for 
drug delivery systems are regarded as a “drugs” 
(both are regarded as medical devices in the 
U.S.). The licensing process for medical devices 
in Japan is similar to those applied to drugs: a 
rigorous and lengthy review process is required.
Although vigilant and discreet evaluation is 
quite justifiable because these products involve 
human lives, however, applying the same review 
process as for the drugs includes apparently 
super f luous steps. Tak ing implantat ion of 
autologous cells for an example, physicians are 
allowed to harvest, multiply and transplant the 
cells at their own discretion on the condition 
that the procedures take place in the hospital 
to  wh ich they  be longs .  However,  i f  the  
multiplication process of the same autologous 
cells takes place in a commercial facility outside 
the hospital, a separate off icial approval is 
required entailing tracking back to the origin of 
the cells. Careful pedigree evaluation of the cells 
is important for non-autologous cells because of 
infectious concerns, but it is highly questionable 
if these verification steps are still needed when it 
is apparent that the cells are autologous.
In the U.S., a straightforward supplemental 
application is available as a method of partial 
modification of the approved items of a medical 
device. With this method, modification of an 
approved medical device can be approved 
promptly. The same situation in Japan requires 
going through the whole application process 
again. Because of this, a case has been reported 
where an imported product cannot be sold in 
Japan due to minor modification: the distributor 
has to stock older parts and assemble or repair 
the device using the older parts to sel l the 
device in the Japanese market[17]. These rigorous 
procedures are applied even to regenerative 
medicine and DDS materials. Efforts should be 
made to minimize the burden for approval for any 
combination of those materials, cells, and medical 
agents that have already been approved, unless 
there could be a possibility of evolving chemical 
reactions among them.
4-2 Conflict of views:
 industry and public administration
Measures towards expediting the examination 
period have been discussed in the Council 
for Science and Technology Policy, and a plan 
to double the number of examiners in three 
years has been announced, but distribution of 
area of expertise of these examiners has not 
been clarif ied. Joint effort between private 
sectors and the Ministry of Health, Labour 
and Wel fare (MHLW) towards speed - up of 
examination is in progress through the activities 
o f  the  Med ica l  E ng i neer i ng  Tech nolog y  
Industrial Strategy Consortium and Regular 
Meeting on Pharmaceutical Regulations of 
Medical Equipment. Unfortunately, it seems 
that communication among these efforts is 
insufficient and we will have to wait for some 
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time before these efforts will deliver concrete 
results.
Table 2 provides a summary of opinions from 
industries and administrations put forward at 
the 5th Regular Meeting on Pharmaceutical 
Regulations of Medical Equipment. The industry 
sector hopes to carry forward clinical trials 
by collecting necessary information and data 
required for application protocol as quickly as 
possible. Consultation meetings can be a good 
tool for accelerating this process. The industry 
sector is generally dissatisfied with the response 
from the administrative side because of the 
lack of rational viewpoint and other reasons 
and feels this can be the major cause of delay in 
approval process. Lack of a rational viewpoint 
causes confusion such as hiatus of important 
data, delay of data processing, and other such 
problems, result ing in the whole process. 
The administrative side, in contrast, has an 
understanding that it has delivered a sufficient 
amount of explanation and advice. On the whole, 
opinions from both sides do not seem to mesh 
well including the interpretation of terminology, 
and might well be resulting on the administrative 
side stipulating more than necessary data to be on 
the safe side.
4-3 Participation in international standardization
Japan has traditionally paid insufficient effort 
for proactive international standardization. There 
is no denying that a passive “just follow what 
others decide” attitude still prevails. The U.S., 
for example, has a standardization organization, 
the American Society for Testing and Materials 
(ASTM) that strongly ref lects U.S. industry’s 
interests. ASTM is quite proactive in establishing 
international de - facto standards and actively 
lobbying to incorporate their interests into the 
International Organization for Standardization 
(ISO) standards.
A welcome sign is that some authorities and 
experts from industry and academia in Japan 
have star ted to participate in regenerative 
medicine related technical committees, such as 
on orthopedics materials and biological materials. 
Also, the drive for the standardization effort can 
be seen among Japanese researchers as evidenced 
by participation in the pre - standardization 
organization of advanced materials, Versailles 
Project on Advanced Materials and Standards 
(VAMAS), from its initial stage. Continued effort 
for this line of activities is strongly desired. The 
Ministry of Health, Labour and Welfare should 
introduce international standards for evaluation of 
medical devices. It is also important to rationalize 
domestic standards and propose them for 
international adaptation, which will surely effect 
to the advantage of Japanese medical devices 
gaining ground in the international market.
5 Conclusion
We have discussed the current status and 
future problems in biomaterial research focused 
on regenerative medicine. Outstanding points 
among the status and problems are as follows.
Table 2 : Difference of view between industry and administration
(at the Regular Meeting on Pharmaceutical Regulations of Medical Equipment)
Views from industry Views from administration
• Delay of examination due to insufficient number of examiners
• Irrational examination process
• Disparity between regulation and development promotion
• Provisions for devices approved in other countries
• Relaxation of regulation on Good Clinical Practice (GCP) 
• Difficulty in using preapplication consultation
• Insufficient quality of application dossier
• Slow flow of information from manufacturer
• Insufficient compliance to what was decided
Common views
• Drug specialists are supported by academia and industry, but there are no academic units to foster medical device specialists.
• Fundamental difference of drugs and medical devices.
(Takashi Wachi: Chairman, the Japan Federation of Medical Devices Associations, Tatsuo Kurokawa: Councilor (Pharmaceuticals), 
Minister’s Secretariat, MHLW)
Compiled by Mr. T. Tateishi (National Institute for Materials Science) based on Reference[18]
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5-1 Control over time of cell environment and
 development of scaffold materials to
 support cell environment
To reproduce large functional tissues, it is 
essential to create and control an appropriate 
environment that ensures the growth of cells 
dur ing regenerat ion and avoids necrosis.  
Especially, the development of such materials 
(or arti f icial extracel lular matr ix) that can 
be controlled in terms of three - dimensional 
structure and time so that the cell environment 
can be adapted synchronized to or preceding 
the changes in cell’s functional expression is 
required. Regeneration of organs requires an 
environment in which different types of cells 
can function in cooperative fashion. For this 
purpose, appropriate space must be prepared 
in the t issue environment for the cel ls to 
multiply, differentiate, and develop functions. 
Physicochemical or biochemical conditions 
around the organ change constantly. Future 
scaffold materials that should be developed must 
be able to control the cell environment in terms 
of time and should finally disappear.
5-2 Infrastructure for accelerating
 regenerative medicine research
Timely approval of study products is essential 
to promote practical application of regenerative 
medicine research. One of the bottlenecks 
toward this goal is the fact that some of the 
data required for examination seems to lack 
rational grounds, delaying the approval process 
of new regenerative medical products. Another 
deplorable problem is the conf lict of views 
that are still persisting between industries and 
administrative communities. An effective measure 
against the delay of approval processes and for 
the establishment of an effective system will be to 
foster experts with ample knowledge in medicine 
and pharmaceutical science, and allocate them to 
authorization organizations or medical facilities. 
Establ ish ing a new national qual i f icat ion, 
corresponding for example to a pharmacist, 
may be a good idea. Distribution of such expert 
personnel is also important from the perspective 
of maintaining medical equipment that becomes 
increasingly specia l ized and complex and 
preventing medical malpractice due to erroneous 
instrument use. An equally important factor is 
the effort to establish international standards 
for medical and technological evaluation that is 
acceptable or favorable to Japan. This will have a 
tremendous effect on both acceleration of clinical 
trials and dissemination of products in the world 
market, thus stimulating the medical industry in 
charge of practical realization of research results.
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Glossary
*1 Hyd rox yapat i te  i s  a  ma i n  i nor ga n ic  
const i tuent  of  ver tebrate  bones  and 
tooth.  Hydrox yapat i te  may fou nd a s  
calcium-deficient hydroxyapatite, sodium 
hydroxyapatite, magnesium hydroxyapatite, 
hydroxyapatite of which carbonate group is 
replaced with phosphate group or hydroxyl 
group; and those of which hydroxyl group is 
replaced with fluorine.
*2 Bu f fer solut ion that has nearly equa l 
inorganic components as human plasma. 
When bioactive ceramics (capable of direct 
connection with bones inside the body) 
is immersed in this f luid, fine crystals of 
carbonic acid containing hydroxyapatite is 
deposited on its surface.
*3 Most cells except blood cells and other cell 
types in suspension need to be fixed on 
matrix for multiplication and differentiation. 
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Cells in the body are adhered to extracellular 
matrix such as basal membrane. For effective 
in vitro mult ipl icat ion and functional 
expression of cells, alternative extracellular 
matrix is required. Such matrix is called a 
scaffold. Currently, porous materials made of 
collagen, polylactic acid, and hydroxyapatite 
are used.
*4 S i nce  regener a t ion  o f  ca r t i l age  a nd  
surrounding bone tissues is impossible 
in patients with degenerative arthritis, 
their diseased joints are often replaced 
with artificial joints made of metal and 
ceramics. This is a viable method because 
the main function of cartilage is mechanical. 
However,  prolonged use of  a r t i f ic ia l  
joints can cause problems in joining area 
with bone and sliding surfaces; hence an 
alternative regenerative method is highly 
desirable.
*5 E l d e r l y  p e o p l e  g e n e r a l l y  r e t a i n  a  
considerable degree of bone formation 
c a p a c i t y,  b u t  m a n y  o f  t h e m  h a v e  
osteoporosis. For safety reasons, many 
physicians prefer mater ials containing 
osteoblasts.
*6 Rotating wall vessels are uniaxial rotating 
culture apparatuses used to produce a 
pseudo microgravity environment, which 
are derived from technology developed by 
NASA. Klinostats are also rotating culture 
apparatuses capable of producing even 
better a pseudo microgravity environment 
by rotating 3-dimensionally.
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